| P2093 | author name string | Peng Li | |
| | Lei Cai | |
| | Zhiqiang Chen | |
| | Yi Zheng | |
| | Jian Yang | |
| | Yulin Guo | |
| | Xinxin Liu | |
| | Guanghai Ji | |
| P2860 | cites work | ESUR prostate MR guidelines 2012 | Q24620926 |
| | Cancer statistics, 2015 | Q27860576 |
| | Tumor angiogenesis: therapeutic implications | Q27860595 |
| | Meta-analysis in clinical trials | Q27860779 |
| | QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies | Q27861031 |
| | American Cancer Society guideline for the early detection of prostate cancer: update 2010 | Q28274848 |
| | The nuts and bolts of PROSPERO: an international prospective register of systematic reviews | Q28736175 |
| | PI-RADS Prostate Imaging – Reporting and Data System: 2015, Version 2 | Q29037908 |
| | The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials | Q29619501 |
| | Evaluation of the prostate imaging reporting and data system for the detection of prostate cancer by the results of targeted biopsy of the prostate | Q30771056 |
| | Cochrane diagnostic test accuracy reviews | Q31140786 |
| | Identification of pathologically insignificant prostate cancer is not accurate in unscreened men. | Q33613656 |
| | Prostate cancer: 1.5 T endo-coil dynamic contrast-enhanced MRI and MR spectroscopy--correlation with prostate biopsy and prostatectomy histopathological data. | Q33657824 |
| | Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. | Q33744660 |
| | The accuracy of multiparametric MRI in men with negative biopsy and elevated PSA level--can it rule out clinically significant prostate cancer? | Q33848437 |
| | Molecular differences in transition zone and peripheral zone prostate tumors | Q36067907 |
| | Dynamic contrast enhanced MRI in prostate cancer | Q36906401 |
| | Prostate cancer detection: the value of performing an MRI before a biopsy | Q84798199 |
| | Prostate cancer detection in patients with total serum prostate-specific antigen levels of 4-10 ng/mL: diagnostic efficacy of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging | Q84813636 |
| | The clinical value of dynamic contrast-enhanced magnetic resonance imaging at 3.0T to detect prostate cancer | Q87500266 |
| | A "PSA pyramid" for men with initial prostate-specific antigen ≤3 ng/ml: a plea for individualized prostate cancer screening | Q87806928 |
| | Prostate cancer: relationships between postbiopsy hemorrhage and tumor detectability at MR diagnosis | Q37186380 |
| | Understanding heterogeneity in meta-analysis: the role of meta-regression | Q37600940 |
| | Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. | Q37937948 |
| | Detection of prostate cancer with magnetic resonance imaging: optimization of T1-weighted, T2-weighted, dynamic-enhanced T1-weighted, diffusion-weighted imaging apparent diffusion coefficient mapping sequences and MR spectroscopy, correlated with bi | Q37977299 |
| | Imaging in prostate cancer staging: present role and future perspectives. | Q37979650 |
| | Multiparametric MRI and prostate cancer diagnosis and risk stratification. | Q38012217 |
| | Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management. | Q38012717 |
| | Transition zone prostate cancer: detection and localization with 3-T multiparametric MR imaging. | Q38059100 |
| | Role of MRI in prostate cancer detection | Q38089710 |
| | 1.5-T multiparametric MRI using PI-RADS: a region by region analysis to localize the index-tumor of prostate cancer in patients undergoing prostatectomy | Q38211143 |
| | Models and methods for analyzing DCE-MRI: a review. | Q38282639 |
| | Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature | Q38346015 |
| | DCE MRI of prostate cancer. | Q38837802 |
| | Prospective comparison of T2w-MRI and dynamic-contrast-enhanced MRI, 3D-MR spectroscopic imaging or diffusion-weighted MRI in repeat TRUS-guided biopsies | Q39944232 |
| | Prostate cancer detection by prebiopsy 3.0-Tesla magnetic resonance imaging | Q39992577 |
| | Prostate Cancer: Screening, Diagnosis, and Management | Q40486134 |
| | Combined prostate diffusion tensor imaging and dynamic contrast enhanced MRI at 3T--quantitative correlation with biopsy | Q41822887 |
| | Preoperative detection of prostate cancer: a comparison with 11C-choline PET, 18F-fluorodeoxyglucose PET and MR imaging | Q43078732 |
| | Prostate cancer: added value of subtraction dynamic imaging in 3T magnetic resonance imaging with a phased-array body coil. | Q43211072 |
| | Prostate MRI: can we do without DCE sequences in 2013? | Q44036399 |
| | Does 11C-choline PET-CT contribute to multiparametric MRI for prostate cancer localisation? | Q44322324 |
| | Prostate cancer detection with 3 T MRI: comparison of diffusion-weighted imaging and dynamic contrast-enhanced MRI in combination with T2-weighted imaging | Q44386860 |
| | 3.0 T multiparametric prostate MRI using pelvic phased-array coil: utility for tumor detection prior to biopsy | Q44477215 |
| | Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging | Q44566113 |
| | Usefulness of prebiopsy multifunctional and morphologic MRI combined with free-to-total prostate-specific antigen ratio in the detection of prostate cancer | Q45011095 |
| | Prostate cancer foci detected on multiparametric magnetic resonance imaging are histologically distinct from those not detected | Q45235483 |
| | The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. | Q47372679 |
| | NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016. | Q47621362 |
| | A role of multifactorial evaluation of prostatic 3T MRI in patients with elevated prostatic-specific antigen levels: prospective comparison with ultrasound-guided transrectal biopsy. | Q50922725 |
| | Transition zone prostate cancer: revisiting the role of multiparametric MRI at 3 T. | Q50954987 |
| | Wash-in rate on the basis of dynamic contrast-enhanced MRI: usefulness for prostate cancer detection and localization. | Q51963017 |
| | Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer. | Q53047832 |
| | Prostate cancer detection with magnetic resonance imaging: is dynamic contrast-enhanced imaging necessary in addition to diffusion-weighted imaging? | Q53074104 |
| | The value of dynamic contrast-enhanced MRI in the detection of recurrent prostate cancer after external beam radiotherapy: correlation with transrectal ultrasound and pathological findings. | Q53278850 |
| | Localization of prostate cancer using 3T MRI: comparison of T2-weighted and dynamic contrast-enhanced imaging. | Q53607604 |
| | Leveling of prostate cancer mortality in Western Europe | Q56994905 |
| | Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection | Q63966218 |
| | Dynamic Contrast-enhanced–magnetic Resonance Imaging Evaluation of Intraprostatic Prostate Cancer: Correlation with Radical Prostatectomy Specimens | Q63966229 |
| | Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localizing prostate cancer before repeat biopsy | Q63966476 |
| | Comparison of microscopic vascularity in benign and malignant prostate tissue | Q70559184 |
| | Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity | Q71608229 |
| | Epidemiology of prostate cancer | Q73742526 |
| | Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? | Q74591846 |
| | Value of multiparametric prostate MRI of the peripheral zone | Q83237479 |
| | Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers | Q83423979 |
| P433 | issue | 44 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 77975-77989 | |
| P577 | publication date | 2017-08-17 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Accuracy of dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate cancer: systematic review and meta-analysis | |
| P478 | volume | 8 | |